-62%

est. 2Y upside i

HealthcareSeries D+

Biograph is on a mission to drive meaningful advances in human healthspan and lifespan. We're not simply focused on helping you live longer. We're focused on making every year the best it can be. Because how well you live is as important as how long you live.

Rank

#3687

Sector

Healthcare Services

Est. Liquidity

~2Y

Data Quality

Data: Medium

Biograph operates in a high-growth, high-end preventative health niche, with estimated current revenue of ~$23M and recent employee growth of 63%.

Last updated: March 10, 2026

Bull (20%)+100%

Biograph successfully expands its clinic footprint, gains further traction in the high-end preventative health market, and potentially secures partnerships that validate its approach, driving revenue to $50M+ and justifying a $370M+ valuation (2x current) as the longevity market matures and regulatory scrutiny somewhat eases.

Base (35%)+20%

Biograph maintains its niche in the premium preventative health market with steady, albeit slower, growth, reaching approximately $30M in revenue. The company continues to face regulatory headwinds and strong competition, leading to a modest valuation increase to around $222M.

Bear (45%)-40%

Increased regulatory pressure from bodies like the American College of Radiology, coupled with intense competition and a lack of widespread insurance coverage, significantly hampers growth. Revenue stagnates or declines, leading to a down round or acquisition at a valuation of $111M or less, severely impacting common stock value due to liquidation preferences.

Est. time to liquidity~2.0 years

Preference Stack Risk

high

Investors hold $54M in liquidation preferences, meaning common shareholders would receive proceeds only after this amount is paid out in an exit.

Dilution Risk

moderate

As a later-stage company with high capital intensity and ongoing expansion, future funding rounds are possible, which could lead to additional dilution.

Secondary Liquidity

none

There is no public information suggesting active secondary markets or tender offers for Biograph's equity.

Other — 10 roles

View all 10 open roles at Biograph →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Biograph's data — designed to show you've done your homework.

  • 1

    “How is Biograph actively addressing the American College of Radiology's stance on whole-body screening for asymptomatic individuals, and what strategies are in place to generate clinical evidence supporting the long-term efficacy and cost-effectiveness of your services?”

  • 2

    “Given the high capital intensity of operating diagnostic clinics and a $7,500 membership fee, what is Biograph's long-term strategy for scaling operations, potentially expanding beyond affluent markets, and achieving profitability?”

  • 3

    “With $54M in total funding and a current estimated valuation of $185M, how does Biograph envision the path to a liquidity event (IPO or acquisition) within the next 2-3 years, and what are the company's plans for managing potential future dilution for employees?”

Community

Valuation Sentiment

Our model estimates -62% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.